CDC42 and glioblastoma: In summary, our obtained results showed that CCNB1/CDC42/MAPK7/CD44 oncogenic signatures are potential biomarkers of GBM therapeutic-resistant tumors, and potential drug targets of our novel small molecule, SJ10.